616890-56-3

Basic information

• Product Name: 3-tert-butyl-1-(4-methoxybenzyl)-1,2,3,4-tetrahydroquinazoline-2,4-dione
• Synonyms: 3-tert-butyl-1-(4-methoxybenzyl)-1,2,3,4-tetrahydroquinazoline-2,4-dione
• CAS NO: 616890-56-3
• Molecular Weight: 338.406
• Mol File: 616890-56-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-tert-butyl-1-(4-methoxybenzyl)-1,2,3,4-tetrahydroquinazoline-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-tert-butyl-1-(4-methoxybenzyl)-1,2,3,4-tetrahydroquinazoline-2,4-dione(616890-56-3)
• EPA Substance Registry System: 3-tert-butyl-1-(4-methoxybenzyl)-1,2,3,4-tetrahydroquinazoline-2,4-dione(616890-56-3)

Safety Data

• Hazardous Substances Data: 616890-56-3(Hazardous Substances Data)

Upstream product

• 616890-29-0 N-tert-butyl-N′-(methoxycarbonyl)-2-aminobenzamide 
• 1203-89-0 2-amino-N-(1,1-dimethylethyl)benzamide 
• 118-48-9 isatoic anhydride 
• 824-94-2 p-methoxybenzyl chloride 
• 1209-77-4 3-tert-butyl-1,2,3,4-tetrahydroquinazoline-2,4-dione 

Downstream Products

• 616890-30-3 1-(4-methoxybenzyl)-1,2,3,4-tetrhydroquinazoline-2,4-dione 

Relevant articles and documents

1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.